See more : Faircourt Gold Income Corp. (FRCGF) Income Statement Analysis – Financial Results
Complete financial analysis of Acepodia, Inc. (6976.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acepodia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Binjiang Service Group Co. Ltd. (3316.HK) Income Statement Analysis – Financial Results
- Macquarie Telecom Group Limited (MAQ.AX) Income Statement Analysis – Financial Results
- Quilter plc (QLT.L) Income Statement Analysis – Financial Results
- Basin Uranium Corp. (BURCF) Income Statement Analysis – Financial Results
- Tata Teleservices (Maharashtra) Limited (TTML.NS) Income Statement Analysis – Financial Results
Acepodia, Inc. (6976.TWO)
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its unique antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. The company was founded in 2017 and is headquartered in Grand Cayman, the Cayman Islands.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 16.59M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.59M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 310.94M | 341.59M | 303.45M | 115.53M |
| General & Administrative | 141.63M | 175.97M | 173.84M | 34.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 141.63M | 175.97M | 173.84M | 34.12M |
| Other Expenses | 0.00 | -920.85M | -400.85M | -305.54M |
| Operating Expenses | 452.57M | 517.56M | 477.29M | 149.64M |
| Cost & Expenses | 452.57M | 517.56M | 477.29M | 149.64M |
| Interest Income | 132.24M | 25.55M | 424.00K | 279.00K |
| Interest Expense | 4.84M | 1.51M | 798.00K | 60.00K |
| Depreciation & Amortization | 47.18M | 22.99M | 12.11M | 4.29M |
| EBITDA | -764.52M | -1.39B | -865.61M | -146.75M |
| EBITDA Ratio | -4,607.48% | 0.00% | 0.00% | 0.00% |
| Operating Income | -435.97M | -1.41B | -477.29M | -149.64M |
| Operating Income Ratio | -2,627.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -380.57M | -896.81M | -401.22M | -305.32M |
| Income Before Tax | -816.54M | -1.41B | -878.51M | -454.96M |
| Income Before Tax Ratio | -4,921.01% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 776.00K | 0.00 | -400.43M | -305.26M |
| Net Income | -817.32M | -1.41B | -878.51M | -454.96M |
| Net Income Ratio | -4,925.69% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -30.79 | -77.69 | -40.23 |
| EPS Diluted | -1.44 | -30.79 | -77.69 | -40.23 |
| Weighted Avg Shares Out | 567.02M | 45.94M | 11.31M | 11.31M |
| Weighted Avg Shares Out (Dil) | 567.02M | 45.94M | 11.31M | 11.31M |
Source: https://incomestatements.info
Category: Stock Reports